Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Real Time Quote from BATS)
$6.95 USD
+0.15 (2.21%)
Updated Aug 8, 2025 02:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDRX 6.95 +0.15(2.21%)
Will BDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock
BDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade
Other News for BDRX
ADR Ratio Change Effective | BDRX Stock News
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover ...
Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance